Probiotics (Bacteroides fragilis bf-839) enhance the efficacy and reduce side effects of anti-PD-1 antibody in the treatment of lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054558

Enrollment

Unknown

Registered

2021-12-19

Start date

2021-05-13

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Experimental group:Probiotics

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed with locally advanced (stage IIIV) or metastatic (stage IV) non-small cell lung cancer who are not suitable for surgery or radiotherapy; 2. PD-1 treatment for the first time; 3. ECOG physical condition score 0-1 points; 4. Aged 18 to 75 years.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Progression free survival;	—

Countries

China

Contacts

Public ContactDeng Yuhong

The Second Affiliated Hospital of Guangzhou Medical University

1376708863@qq.com+86 18926179290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026